Published: 2018-12-17

Acne & Rosacea

FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Efficacy and Safety From a Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study

Joseph Raoof, Deirdre Hooper, Angela Moore, Martin Zaiac, Tory Sullivan, Leon Kircik, Edward Lain, Jasmina Jankivevic, Iain Stuart
| DOI https://doi.org/10.25251/skin.2.supp.56

Page S56

Poster PDF

Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance

Rhonda Schreiber, Caitlin Lewis, Kaytiana Crane
| DOI https://doi.org/10.25251/skin.2.supp.57

Page S57

Poster PDF

Novel Tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a Hispanic population

Fran E Cook-Bolden, Susan H Weinkle, Eric Guenin, Varsha Blatt
| DOI https://doi.org/10.25251/skin.2.supp.58

Page S58

Poster PDF

Novel Tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: Assessment of safety and tolerability in subgroups

Joshua A Zeichner, Julie C Harper, Wendy E Roberts, Et al.
| DOI https://doi.org/10.25251/skin.2.supp.59

Page S59

Poster PDF

Atopic Dermatitis

Patient-reported outcomes in subjects with atopic dermatitis treated with tapinarof cream: Results from a phase 2b, randomized parallel-group study

Amy S Paller, Linda Stein Gold, James Lee, Anna M Tallman, David Rubenstein
| DOI https://doi.org/10.25251/skin.2.supp.60

Page S60

Poster PDF

GBR 830 Induced Progressive and Sustained Improvements in Atopic Dermatitis Skin Biomarkers and Clinical Parameters

Emma Guttman-yassky, Ana B Pavel, Yeriel Estrada, Lisa Zhou, Yacine Salhi, Girish Gudi, Vinu Ca, Julie Macoin, Jonathan Back, Gerhard Wolff
| DOI https://doi.org/10.25251/skin.2.supp.61

Page S61

Poster PDF

Targeting OX40 With GBR 830, An OX40 Antagonist, Inhibits T Cell-Mediated Pathological Responses

Julie Macoin, Rami Lissilaa, Pavankumar Sancheti, Venkateshwar Reddy, Jonathan Back, Gerhard Wolff
| DOI https://doi.org/10.25251/skin.2.62

Page S62

Poster PDF

Risk of anaphylaxis and conjunctivitis with tralokinumab in atopic dermatitis

Andreas Wollenberg, Emma Guttman-Yassky, Mathias Torpet, Jonathan I Silverberg
| DOI https://doi.org/10.25251/skin.2.supp.63

Page S63

Poster PDF

Treatment with tralokinumab improves health-related quality of life in adult patients with moderate to severe atopic dermatitis: results from a Phase 2b, randomised, double-blind, placebo-controlled study

Jonathan I Silverberg, Nana Kragh, Emma Guttman-Yassky, Andreas Wollenberg
| DOI https://doi.org/10.25251/skin.2.supp.64

Page S64

Poster PDF

The Importance of Skin Barrier Function in Atopic Dermatitis Patients

Michael H Gold
| DOI https://doi.org/10.25251/skin.2.supp.65

Page S65

Poster PDF

Hyperhidrosis

Clinical Management of Anticholinergic Adverse Events with Glycopyrronium Cloth, a Treatment for Primary Axillary Hyperhidrosis

D Pariser, R Gopalan, J Drew, L Green
| DOI https://doi.org/10.25251/skin.2.supp.66

Page S66

Poster PDF

Onset of Action With Glycopyrronium Cloth in the Treatment of Primary Axillary Hyperhidrosis

D Pariser, L Green, J Drew, R Gopalan, V Yan, D Glaser
| DOI https://doi.org/10.25251/skin.2.supp.67

Page S67

Poster PDF

Short- and Long-Term Efficacy and Safety of Glycopyrronium Cloth for the Treatment of Primary Axillary Hyperhidrosis: Post Hoc Pediatric Subgroup Analyses from the Phase 3 Studies

Adelaide A Hebert, Dee Anna Glaser, Lawrence Green, William P Werschler, Douglass W Forsha, Janice Drew, Ramanan Gopalan, David M Pariser
| DOI https://doi.org/10.25251/skin.2.supp.68

Page S68

Poster PDF

Melanoma

Real-world experience and clinical utility of a non-invasive gene expression rule-out test for melanoma and additional validation against high risk driver mutations in BRAF, NRAS and the TERT promoter

Laura Ferris, Burkhard Jansen, Zuxu Yao, Jim Rock, Maral Skelsey, Gary Peck, Clay J Cockerell
| DOI https://doi.org/10.25251/skin.2.supp.69

Page S69

Poster PDF

Improvement of risk assessment in cutaneous melanoma (CM) by a prognostic 31-gene expression profile (31-GEP) test over AJCC-based staging alone

Giselle Prado, Robert W Cook, Kyle R Covington, Federico A Monzon, Darrell S Rigel
| DOI https://doi.org/10.25251/skin.2.supp.70

Page S70

Poster PDF

Literature review of a prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma (CM) risk prediction

Robert W Cook, Kristen M Plasseraud, Sarah J Kurley, Kyle R Covington, Federico A Monzon
| DOI https://doi.org/10.25251/skin.2.71

Page S71

Poster PDF

Non-Melanoma Skin Cancers and Benign Cutaneous Tumors

Combination Therapy with Short Contact Topical Calcipotriene Foam and Fluorouracil Following Cryotherapy for Actinic Keratosis

Angela Y Moore, Madalyn Nguyen
| DOI https://doi.org/10.25251/skin.2.supp.72

Page S72

Poster PDF

Assessing Patient Concerns Regarding Seborrheic Keratoses on the Face: Comparison Against Other Cosmetic Concerns

Shuai Xu, Stacy Wang
| DOI https://doi.org/10.25251/skin.2.supp.73

Page S73

Poster PDF

The Hidden Impact of Seborrheic Keratoses: Analysis of a Psychometric Survey of an Ethnically Diverse Cohort of U.S. Adults

Shuai Xu, Stacy Wang, Esther Estes
| DOI https://doi.org/10.25251/skin.2.supp.74

Page S74

Poster PDF

Open-Label Study of A-101, a 40% Hydrogen Peroxide Topical Solution, in Patients With Seborrheic Keratosis

Valerie Callender, Ellen Frankel, Jonathan Weiss, William Werschler, Christopher Powala, Brian Beger, Esther Estes, Stuart Shanler
| DOI https://doi.org/10.25251/skin.2.supp.75

Page S75

Poster PDF

VDA-1102 : A Novel Well-Tolerated Treatment For Actinic Keratosis

Chaim M Brickman, Vered Behar, Galit Zelinger, Oren M Becker
| DOI https://doi.org/10.25251/skin.2.supp.76

Page S76

Poster PDF

Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Michael R Migden, Carola Berkin, Anne Lynn Chang, Et al.
| DOI https://doi.org/10.25251/skin.2.supp.77

Page S77

Poster PDF

Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data

Taofeek K Owonikoko, Kyriakos P Papadopoulos, Melissa L Johnson, Et al.
| DOI https://doi.org/10.25251/skin.2.supp.78

Page S78

Poster PDF

Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma

Danny Rischin, Michael R Migden, Anne Lynn S Chang, Et al.
| DOI https://doi.org/10.25251/skin.2.supp.79

Page S79

Poster PDF

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis

A Teeple, E Muser
| DOI https://doi.org/10.25251/skin.2.supp.81

Page S80

Poster PDF

Assessing the Relationship Between Disease Severity and Patient-Reported Outcomes in Psoriasis Patients in the US

J Lucas, A Teeple, J Hetherington, E Muser
| DOI https://doi.org/10.25251/skin.2.supp.82

Page S81

Poster PDF

Economic Burden of Comorbid Anxiety and Depression among Patients with Moderate to Severe Psoriasis

Q Cai, A Teeple, B Wu, Et al.
| DOI https://doi.org/10.25251/skin.2.supp.83

Page S82

Poster PDF

A Randomized, Parallel-Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with a New Lower-Concentration (0.025%) Clobetasol Propionate Cream

Zoe D Draelos, Joseph F Fowler, Raymond Cornelison
| DOI https://doi.org/10.25251/skin.2.supp.84

Page S83

Trends in Prevalence of Psychiatric Comorbidities among Patients with Moderate to Severe Psoriasis

Q Cai, A Teeple, B Wu, S Shrivastava, E Muser
| DOI https://doi.org/10.25251/skin.2.supp.85

Page S84

Poster PDF

Patient-reported outcomes in subjects with plaque psoriasis treated with tapinarof cream: Results from a phase 2b, randomized parallel-group study

Neal Bhatia, David Rubenstein, Anna M Tallman, James Lee
| DOI https://doi.org/10.25251/skin.2.supp.86

Page S85

Poster PDF

Clinical Response in Plaque Psoriasis Patients Switching from Etanercept to Certolizumab Pegol in a Phase 3, Randomized, Controlled Study

M Augustin, J Wegtowska, M Lebwohl, C Paul, V Piguet, H Sofen, A Blauvelt, L Peterson, C Arendt, R Rolleri
| DOI https://doi.org/10.25251/skin.2.supp.87

Page S86

Poster PDF

Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)

M Augustin, J Wegtowska, M Lebwohl, C Paul, V Piguet, H Sofen, A Blauvelt, L Peterson, Et al.
| DOI https://doi.org/10.25251/skin.2.supp.88

Page S87

Poster PDF

Frequency of Inadequate Response to Treatment Among Psoriasis Patients on First-Line Biologics

A Sheahan, E Lee, L Pisenti, M Yassine, R Suruki
| DOI https://doi.org/10.25251/skin.2.supp.89

Page S88

Poster PDF

A Comprehensive Survey Assessing the Family Planning Needs of Women with Psoriasis

M Lebwohl, M Siegel, L Shankle, L Pisenti, M Yassine, S Van Vorhees
| DOI https://doi.org/10.25251/skin.2.supp.90

Page S89

Poster PDF

Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis

CEM Griffiths, KA Papp, M Song, B Randazzo, S Li, YK Shen, C Han, A Blauvelt
| DOI https://doi.org/10.25251/skin.2.supp.91

Page S90

Poster PDF

Calcipotriene plus betamethasone dipropionate (0.005%/0.064%) foam and apremilast: matching-adjusted indirect comparison and US cost per responder analyses

Martin E Nyeland, Lidia Becia, Dharm S Patel, Karen A Veverka, Andrine R Swensen
| DOI https://doi.org/10.25251/skin.2.supp.92

Page S91

Poster PDF

Dual neutralization of IL-17A and IL-17F with bimekizumab improves quality of life in patients withmoderate-to-severe plaque psoriasis: results from a Phase 2b study and correlation with clinical response

Kim A Papp, Joseph F Merola, Alice B Gottlieb, Et al.
| DOI https://doi.org/10.25251/skin.2.supp.93

Page S92

Poster PDF

Patient Perception of Vehicle and How This Influences Adherence to Topical Treatment Regimens

Steven R Feldman, Rhonda Schreiber, Kaytiana Crane, Madelyn Comito
| DOI https://doi.org/10.25251/skin.2.supp.94

Page S93

Poster PDF

An Update on the Long-Term Safety Experience of Ixekizumab: Results from the Psoriasis Clinical Development Program with More than 3 Years of Follow-up from 12 Clinical Trials and More Than 15000 Patient-Years of Exposure to Ixekizumab

April Armstrong, Noah Agada, Wen Xu, Gaia Gallo
| DOI https://doi.org/10.25251/skin.2.supp.105

Page S116

Poster PDF

Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients With Moderate-to-Severe Plaque Psoriasis: 52-Week Data From the IXORA-S Trial

Norman Wasel, Yves Dutronc, Birgit Schinzel, Jean-Philippe Lacour
| DOI https://doi.org/10.25251/skin.2.supp.106

Page S117

Poster PDF

Efficacy of Ixekizumab in Patients Previously Treated with IL-17 Inhibitors

Kim A Papp, Andrew Blauvelt, John Sullivan, Et al.
| DOI https://doi.org/10.25251/skin.2.supp.107

Page S118

Poster PDF

Miscellaneous

Treatment of Palmo-plantar Keratoderma of Unna-Thost with Tazarotene Foam 0.1%

Farooq Lateef, Hanna Lateef
| DOI https://doi.org/10.25251/skin.2.supp.80

Page S94

Poster PDF

Rising Derm Stars® Abstracts

The microbiome in preadolescent acne: assessment and prospective analysis on the influence of benzoyl peroxide

Jusleen Ahluwalia
| DOI https://doi.org/10.25251/skin.2.supp.95

Page S95-S96

Poster PDF

Association of Pemphigus and Pemphigoid with Osteoporosis and Pathological Fractures

Raj Chovatiya
| DOI https://doi.org/10.25251/skin.2.supp.96

Page S97-S98

Poster PDF

Prophylactic botulinum toxin in post-excisional scars: a randomized, doubleblinded, controlled clinical trial

Danielle Dubin

Page S99-S100

Poster PDF

Optical Coherence Tomography for the Scalp

Chloe Ekelem
| DOI https://doi.org/10.25251/skin.2.supp.97

Page S101-S102

Poster PDF

Topical Cantharidin Revisited: A Phase 2 Study Investigating a Commercially-Viable Formulation of Cantharidin (VP-102) for the Treatment of Molluscum Contagiosum

Anthony Guzman
| DOI https://doi.org/10.25251/skin.2.supp.98

Page S103-S104

Poster PDF

Silver Sulfadiazine retards wound healing in mice via alterations in cytokine expression

Angelo Landriscina
| DOI https://doi.org/10.25251/skin.2.supp.99

Page S105-S106

Poster PDF

Off-Label Treatment of Prurigo Nodularis with Dupilumab: A Case Series Study

Nicholas Mollanazar
| DOI https://doi.org/10.25251/skin.2.supp.100

Page S107-S108

Poster PDF

Non-Invasive Buccal Swab Gene Testing for Skin Cancer Risk

Lauren Moy
| DOI https://doi.org/10.25251/skin.2.supp.101

Page S109

Poster PDF

Topical JAK inhibitor Ruxolitinib for Vitiligo Treatment

Brooke Rothstein
| DOI https://doi.org/10.25251/skin.2.supp.102

Page S110-S111

Poster PDF

Staphylococcus Aureus Nasal Colonization is Associated with Severity of Radiation Dermatitis in Patients Receiving Radiotherapy

Alexandra Rzepecki
| DOI https://doi.org/10.25251/skin.2.supp.103

Page S112-113

Poster PDF

Inhibition of isoprenoid synthesis synergizes with MAPK blockade to prevent growth in targeted therapy-resistant melanoma

Nicholas Theodosakis
| DOI https://doi.org/10.25251/skin.2.supp.104

Page S114-S115

Poster PDF